Astrazeneca Today Announced That It Has Received Marketing Authorisation From China'S National Medical Products Administration (Nmpa) For Tagrisso (Osimertinib) As A 1St-Line Treatment For Adults With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumours Have The Genetic Mutations Of Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletions Or Exon 21 (L858R) Substitutions.The Approval Followed The Priority Review Pathway And Is Based On Results From The Phase Iii Flaura Trial, Which Were Published In The New England Journal Of Medicine.Dave Fredrickson, Executive Vice President, Oncology, Said:
